Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.
Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C. Postorino MC, et al. Among authors: torti c. BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z. BMC Infect Dis. 2017. PMID: 28298195 Free PMC article.
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.
Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G; HIV-HCV Co-Infection Study Group. Puoti M, et al. Among authors: torti c. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):259-67. doi: 10.1097/00126334-200303010-00004. J Acquir Immune Defic Syndr. 2003. PMID: 12626885 Clinical Trial.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: torti c. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Torti C, et al. J Infect Dis. 2003 Jul 15;188(2):194-201. doi: 10.1086/376512. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854073
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F, Leone L, Patroni A, Castelli F, Ripamonti D, Tramarin A, Carosi G. Torti C, et al. Health Policy. 2003 Sep;65(3):261-7. doi: 10.1016/s0168-8510(03)00002-2. Health Policy. 2003. PMID: 12941493
438 results